These press releases are for business and financial media.
-
- 23 May 2005
- SYMBICORT® SINGLE INHALER THERAPY™ GIVES GREATER IMPROVEMENT IN ASTHMA CONTROL AND REQUIRES LESS INHALERS COMPARED TO SERETIDE™ AstraZeneca today announced that its novel treatment regimen, SYMBICORT® Single Inhaler TherapyTM delivers greater improvement in key measures of asthma control and simplifies management of the disease when compared to SeretideTM (fluticasone/salmeterol).
-
- 11 May 2005
- EPO RULES SYMBICORT® COPD PATENT VALID AstraZeneca today announced that the European Patent Office (EPO) has ruled that the European patent for Symbicort® in the treatment of Chronic Obstructive Pulmonary Disease (COPD) is still valid, despite a challenge by generic manufacturers.
-
- 04 May 2005
- FIRST RESULTS FROM SAINT I TRIAL SHOW ASTRAZENECA’S CEROVIVE (NXY-059) DEMONSTRATES A REDUCTION IN DISABILITY IN PATIENTS WITH ACUTE ISCHEMIC STROKE AstraZeneca today announced that a first analysis of data from the SAINT I trial involving more than 1700 patients shows a statistically significant reduction versus placebo on the primary outcome of disability after an acute ischemic stroke (p= 0.038), as measured by the Modified Rankin Scale (MRS). However, on the National Institute of Health Stroke Scale (NIHSS), there was no significant difference between the treatment groups in measurement of change in neurological impairment. The clinical significance
-
- 28 April 2005
- FIRST QUARTER RESULTS 2005 “Record quarterly profits, with first quarter Earnings per Share up 33 percent. Sales up 9 percent.”
-
- 21 April 2005
- ASTRAZENECA FULFILLS APPROVAL COMMITMENT TO MAKE 5MG DOSE OF CRESTOR AVAILABLE IN EU AstraZeneca announced today that agreement has been reached under the EU arbitration procedure on label wording for a 5mg dose of CRESTOR, the cholesterol lowering treatment, paving the way for its availability across the European Union
-
- 01 April 2005
- FDA APPROVES INTRAVENOUS FORMULATION FOR NEXIUM® AstraZeneca today announced that a new administration formulation for its prescription proton pump inhibitor NEXIUM ® (esomeprazole magnesium) has been approved by the US Food and Drug Administration (FDA). NEXIUM I.V. is now approved as an intravenous infusion or injection for the short-term treatment (up to 10 days) of gastroesophageal reflux disease (GERD) patients, with a history of erosive esophagitis, who are unable to take capsules.
-
- 14 March 2005
- ASTRAZENECA PLC BOARD ANNOUNCEMENT AstraZeneca PLC today announced the appointment to the Board of David R. Brennan as an Executive Director with effect from 14 March 2005.
-
- 09 March 2005
- EPO RULES SYMBICORT® COMBINATION PATENT STILL VALID AstraZeneca today announced that the European Patent Office (EPO) has ruled that the European combination patent for Symbicort® is still valid, despite a challenge by several generic manufacturers.
-
- 04 March 2005
- STUDY FINDS SEROQUEL EFFECTIVE AND WELL TOLERATED AstraZeneca today announced results from a study involving elderly patients with Alzheimer’s disease (AD) treated with the atypical antipsychotic SEROQUEL (quetiapine) at the annual meeting of the American Association of Geriatric Psychiatry in San Diego, USA. The study found that SEROQUEL at 200 mg/day was effective in reducing agitation in elderly patients with AD without leading to a decline in cognitive function. SEROQUEL was also generally well tolerated with no incidence of cerebrovascular adverse
-
- 23 February 2005
- FDA APPROVES ASTRAZENECA’S ATACAND® (CANDESARTAN CILEXETIL) FOR THE TREATMENT OF HEART FAILURE AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) ATACAND® (candesartan cilexetil) for the treatment of heart failure (New York Heart Association Class II-IV and ejection fraction less than or equal to 40 percent) to reduce the risk of death from cardiovascular causes and reduce hospitalisations from heart failure. ATACAND is the first ARB in the US to receive an indication for reducing both cardiovascular mortality and
-
- 27 January 2005
- ASTRAZENECA PRESS STATEMENT REGARDING NEW DATA FROM BIG 1-98, PRESENTED IN ST GALLEN, SWITZERLAND. The results from the head-to-head (letrozole v tamoxifen) arms of the BIG 1-98 trial add to the established body of clinical evidence confirming that tamoxifen should no longer be considered the ‘standard’ hormonal treatment for postmenopausal women with early breast cancer (EBC).
-
- 27 January 2005
- FOURTH QUARTER AND FULL YEAR RESULTS 2004 “Strong earnings performance for 2004; good earnings growth anticipated despite recent disappointments.”
-
- 19 January 2005
- FURTHER CLINICAL INFORMATION REQUESTED ON EXANTA® (XIMELAGATRAN) FOR THE PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION IN EUROPE Following the review by the French Regulatory Authority (AFSSAPS) of the Exanta® regulatory submission made in December 2003 AstraZeneca today announced receipt of a request for more information before the drug can be considered for approval of long-term use in Europe.
-
- 04 January 2005
- GEFITINIB (IRESSA™) MARKETING AUTHORISATION APPLICATION WITHDRAWN IN EU AstraZeneca today announced that it is withdrawing the European Marketing Authorisation Application (MAA) for IRESSA™ (gefitinib) in treating patients with non-small cell lung cancer (NSCLC) from the European Medicines Agency (EMEA).
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
